Summary
AdventHealth Advances in Diabetes Research with First FDA-Approved Drug to Delay Onset of Type 1 Diabetes
Introducing Dr. Anna Casu
Dr. Anna Casu is an associate investigator at the AdventHealth Translational Research Institute, who was diagnosed with Type 1 Diabetes at the age of 6. She understands the complexities of the disease and the consequences of delayed diagnoses. Therefore, when the FDA approved a drug that can delay Type 1 Diabetes, Dr. Casu couldn’t be happier to share her insights.
The FDA-Approved Drug that Delays Type 1 Diabetes Onset
Translational Research Institute-AventHealth has been advancing diabetes research through their work with TZIELD. This medication is the first FDA-approved drug that can delay the onset of Type 1 Diabetes.
Administering the Drug
The medication can be administered to people 8 years and older, as an infusion given over 14 days. It starts with a lower dose and gets increased during the first five days to prevent any side effects. Monitoring of blood results is done before and during the infusion to ensure the safety of the person receiving the treatment. However, Dr. Casu does not administer the treatment herself.
The Benefits of Sealed and Cap Zumab
The medication Sealed and Cap Zumab can delay the onset of Type 1 Diabetes by two or three years, reducing the risk of an acute onset and potential long-term complications in the future. This is a milestone in the diabetes research world.
If you or a loved one would like more information about how Translational Research Institute-AventHealth is advancing diabetes research, contact Dr. Casu or visit their website for more information on this groundbreaking treatment.
Note: This is an AI generated transcript, not edited by a staff writer and is solely intended for educational purposes. If you have any questions/concerns, reach out to podcasts@beckershealthcare.com
This episode aired on 01/29/2023 and can be listened here.
Subscribe to Beckers Healthcare Podcast here.
